T wo new pleuromutilin class agents (BC-3205 and BC-3781) have been developed by Nabriva Therapeutics AG (Vienna, Austria) for oral and intravenous treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms and community-acquired bacterial pneumonia (CABP) (6, 8, 9) . BC-3781 and BC-3205 are semisynthetic pleuromutilin derivatives that interfere with bacterial protein synthesis by binding to the peptidyltransferase center of the ribosomal 50S subunit. Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA), Streptococcus pneumoniae, and Haemophilus influenzae represent important causative organisms of ABSSSI and CABP, and BC-3781 and BC-3205 have demonstrated potent activity against these pathogens (6, 8, 9) . In this report, we describe the results of a multilaboratory quality control (QC) trial designed to propose ranges for both BC-3205 and BC-3781 for broth microdilution (MICs in micrograms per milliliter) and disk diffusion (zone diameters in millimeters) methods, following the guidelines published in the Clinical and Laboratory Standards Institute (CLSI) M23-A3 document (4).
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Eight laboratories were used in these studies; however, only seven laboratories are needed to establish a QC range according to the CLSI M23-A3 document (4) . These laboratories were experienced microbiology facilities, and each followed the CLSI procedures for disk diffusion (2) Reference frozen-form broth microdilution panels were prepared by TREK Diagnostics following good manufacturing practice (GMP) guidelines and shipped frozen to all participant sites. Panels contained three lots of cation-adjusted Mueller-Hinton broth (Oxoid, Hampshire, United Kingdom; BBL, Sparks, MD; and Difco, Detroit, MI). Also, panels containing three lots of Haemophilus Test Medium (HTM) and three lots of Mueller-Hinton broth supplemented with 2% to 5% lysed horse blood were provided by the same vendor. Azithromycin, retapamulin (7), and levofloxacin were utilized as control agents. For broth microdilution testing, each laboratory tested replicates of S. aureus ATCC 29213, H. influenzae ATCC 49247, and S. pneumoniae ATCC 49619. Participating laboratories were instructed to read endpoints in accordance with the CLSI M07-A8 document, which states that, for some antimicrobial agents with trailing endpoints, the MIC should be read at the first well that shows a prominent (Ն80%) reduction in growth compared to the control, and tiny buttons of growth should be ignored (1, 3) . Colony counts were performed on drug-free agar media and resulted in the following average counts: S. aureus ATCC 29213 ϭ 4.0 ϫ 10 5 CFU/ml, H. influenzae ATCC 49247 ϭ 5.4 ϫ10 5 CFU/ml, and S. pneumoniae ATCC 49619 ϭ 2.7 ϫ 10 5 CFU/ml. For disk diffusion tests, three different lots of 20-g disks were manufactured by two companies: MAST Group, Merseyside, United Kingdom (BC-3205 lot 257105 and lot 257106 and BC-3781 lot 257108 and lot 257109) and Bio-Rad, Hercules, CA (BC-3205 lot 9L0011 and BC-3781 lot 9L0011). Single lots of comparator disks from BD (Franklin Lakes, NJ) were used: azithromycin (lot 9118096) (15 g), clindamycin (lot 9187750) (2 g), and linezolid (lot 9225172) (30 g). Three manufacturers (Remel, Lenexa, KS; Hardy Diagnostics, Santa Maria, CA; and BBL) were used to produce lots for Mueller-Hinton agar (lot 848387, lot 09352, and lot 9328321), Haemophilus Test Medium (lot 855369, lot 09355, and lot 9336525), and Mueller-Hinton agar with 5% sheep blood (lot 852672, lot 10006, and lot 9350462).
The BC-3205 and BC-3781 MIC results are summarized as proposed ranges in Table 1 and shown in Fig. 1 and 2 . The S. aureus ATCC 29213 results for BC-3205 demonstrated a bimodal MIC distribution (0.06 and 0.12 g/ml), with all results within the proposed 4-dilution-step range of 0.03 to 0.25 g/ml. A slight medium variation occurred with two lots at a mode of 0.06 g/ml and one lot at 0.12 g/ml. BC-3781 tested against the same S. aureus strain (Fig. 1) resulted in a 3 -dilution-step range of 0.06 to 0.25 g/ml (100.0% of results within the proposed range) with no medium variations observed (Table 1) .
H. influenzae ATCC 49247, when tested with BC-3205, produced a 3-doubling-dilution range of 1 to 4 g/ml (Table 1 , Fig. 1 ). Using the results from all laboratories, only 81.8% of these values fell within the calculated range. By excluding the results from an outlier laboratory (laboratory H; BC-3205 modal value of 0.5 g/ml) (10), the percentage of results included in the proposed range increased only to 87.6%; therefore, no range could be proposed. Laboratory H was also an outlier site for the BC-3781 results (10) and was excluded from analysis to provide a MIC range of 0.5 to 2 g/ml for BC-3781, which included 94.3% of the results (slightly below the optimal target of Ն95% but still accepted by the CLSI) (1). For both drugs tested against H. influenzae, a trailing endpoint of 1 doubling dilution was encountered. Sites were instructed to ignore small, pinpoint buttons of growth when interpreting MIC panels (1) .
Lastly, S. pneumoniae ATCC 49619 tested with BC-3205 had a proposed MIC QC range of 0.06 to 0.25 g/ml (100.0% of results within the range; Table 1 , Fig. 1 ), excluding laboratory H, which clearly had an outlier mode of 0.015 g/ml (10). Data from laboratory H were also excluded from the analysis of the BC-3781 MIC Table 1 and Fig. 2 . Using CLSI M23-A3 criteria (4), a 7-mm range of 26 to 32 mm for S. aureus ATCC 25923 and BC-3205 was proposed that included 99.0% of all reported zone diameters. BC-3781 tested against S. aureus ATCC 25923 also produced a QC range of 26 to 32 mm, which included 97.4% of all results (Fig. 2) All clindamycin and linezolid comparator disk diffusion zones were within the CLSI published ranges, and nearly all (99.9%) of the azithromycin disk zones were within QC limits (5). There was very little median zone diameter variance between the lots of disks (BC-3205, Յ2 mm; BC-3781, Յ1 mm), and there were Յ2-mm differences between median zones for the medium lots across all organisms and investigational disks. A trend toward smaller zone diameters was noted with medium lot C against S. pneumoniae ATCC 49619. Future studies should be reviewed for any medium variations.
The results from this multilaboratory QC study were intended to provide the initial ranges for routine susceptibility testing using disk diffusion and broth microdilution methods (2, 3, 5) as these two novel pleuromutilins progress through phase 2 and 3 human clinical trials. All QC ranges for BC-3781 (Table 1) were presented to the CLSI Subcommittee on Antimicrobial Susceptibility Testing (June 2010) and were approved for future publication in the M100 document (1, 5) .
